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Cancer is the second leading cause of death in the United States. Cisplatin is one
of the well-known anti-cancer agents used to treat testicular and ovarian cancers. It
mainly binds to the DNA bases, which leads to cell death. The cytotoxic activity of the
cisplatin analogs is due to the interaction of platinum with nucleotides like adenine at N7
or N1 position and guanine at N7 position. Guanine is the primary target for cisplatin
analogs whereas adenine is the secondary target. Cisplatin analogs, [Pt(Me5dien)(D2O)]2+
[Me5dien = N,N,N’,N’,N’’-pentamethyl diethylene triamine] and [Pt(dien)(D2O)]2+
[dien=diethylene triamine] were synthesized and their effects on AMP and GMP were
studied using NMR spectroscopy. The experiments were conducted to examine the
effects of bulk on 5’-GMP and 5’-AMP. The results suggest that bulk slows down the
reaction with AMP more than with that of GMP. The order of reactivity is Pt(dien)(GMP)
> Pt(dien)(AMP) > Pt(Me5dien)(GMP) > Pt(Me5dien)(AMP). The reaction of the
[Pt(Me5dien)(D2O)]2+ complex with AMP leads to multiple products, some of which
appear to be due to coordination at N1 instead of N7.

x

1.

INTRODUCTION

Cancer is the second leading cause of death in the United States. About one-half
of all men and one-third of all women in the US will develop cancer during their
lifetimes. Today, millions of people are living with cancer or have had cancer (American
Cancer Society [ACS], n.d.). Thirteen percent of all the deaths around the world are due
to cancer. Uncontrolled and unregulated division of cells leads to the formation of a
tumor, a solid mass of cells. Cancer is also known as ‘malignant neoplasm’. Tumors may
be benign, i.e., non-cancerous, and do not spread to the adjacent tissues whereas
malignant tumors are cancerous and spread to different parts of the body through blood
and lymph. There are different kinds of cancers which can develop in almost any organ or
tissue, such as the lung, colon, breast, skin, bones, or nerve tissue.

1.1 Causes of Cancer
Viral and chemical carcinogens
As of today, specific substances that cause cancer are coal tars and their
derivatives like benzene, some hydrocarbons, aniline, asbestos, and many others (ACS,
n.d.). Ionizing radiation from a variety of sources, such as UV rays from the sun, is
known to cause skin cancer. To ensure the public safety, the government has set safety
standards for many substances, including benzene, asbestos, hydrocarbons in the air,
arsenic in drinking water, and radiation. Several viruses are linked to cancer development
in humans, including:
•

Prolonged infection by hepatitis B or C viruses can lead to liver cancer.
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•

One of the herpes viruses, the Epstein-Barr virus, causes infectious
mononucleosis and has been linked to non-Hodgkin lymphomas and
nasopharyngeal cancer.

•

People with human immunodeficiency virus (HIV) have increased risk of
developing cancers, especially Kaposi sarcoma and non-Hodgkin lymphoma.

•

Human papilloma viruses (HPV’s) have been linked to many cancers, especially
those of the cervix, vulva, vagina, anus, and penis.

Oncogenes and tumor suppressor genes
During the 1970s, scientists discovered two particularly important families of genes
related to cancer: oncogenes and tumor suppressor genes.
Oncogenes:
These genes cause cells to grow out of control and become cancer cells. They
are formed by changes or mutations of certain normal genes of the cell called protooncogenes. Proto-oncogenes are the genes that normally control how often a cell
divides and the degree to which it differentiates or specializes in a specific function in
the body (ACS, n.d.).
Tumor suppressor genes:
These genes are normal genes that control cell division, repair DNA errors,
and tell cells when to die, a process known as apoptosis or programmed cell death.
When tumor suppressor genes do not work properly, cells can grow out of control,
which can lead to cancer (ACS, n.d.).
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The treatment option for various cancers is by surgery. If surgery cannot remove
all of the cancer, the other options include radiation, chemotherapy, or both. Some
cancers require a combination of surgery, radiation, and chemotherapy (ACS, n.d.).
Radiation therapy includes the usage of ionizing radiation, which damages the
DNA of exposed cells or tissue. According to the American Cancer Society (n.d.),
Chemotherapy is the treatment of cancer with drugs that can destroy cancer cells by
impeding their growth and division (ACS, n.d.). It includes the use of different drugs
either individually or in combination. Anticancer activity of these drugs is due to
alteration of DNA structure by binding to it covalently. Anticancer agents are rarely used
singly; they are mostly used in the combination of other anticancer agents. For example,
5-fluoro uracil and Cisplatin or cis-DDP, when given in the combination showed
increased DNA adduct formation. They are not as effective when used separately as they
are in combination. Cisplatin was one of the well-known drugs used in the treatment of
cancer.

1.2 Discovery of cisplatin as an anticancer agent
Barnett Rosenberg, a biophysical scientist at University of Michigan decided to
examine the role of electric currents in cell division. When Escherichia coli, also referred
to as E. coli, cell growth was observed by placing them in the ammonium chloride buffer
medium and a current applied through inert platinum electrodes, E. coli cells appeared as
long and filamentous instead of classical sausage shape after a period of time. This affect
was due to the inhibition of the cell division. Later, it was found that the hydrolysis
products of platinum from the platinum electrodes were responsible for the growth
inhibition but not the electric current.
3

Figure 1: Structure of Cisplatin or cis-DDP. (Wiltshaw & Kroner, 1976).
The 10th group of transition metal compounds were tested for activity, of which
the (NH4)2(PtCl6) salt was found to be more effective. Detailed chemical analysis of this
study identified two active complexes: the neutral cis-isomer [Pt(II)(NH3)2Cl2], which
went on to be known as cisplatin, shown in Figure 1, and a platinum(IV) analogue, as cisdiamminetetrachloroplatinum. These molecules are responsible for inhibitory effect on
the cancer cells. The trans forms of Pt(II) and Pt(IV) complexes were found to be
ineffective when compared to the cis forms (Rosenberg, VanCamp, & Krigas, 1965).
In 1968, further tests were conducted on various bacteria. Cisplatin was
administered intra-peritoneally to mice bearing a standard murine transplantable tumor,
sarcoma-180, which was shown to cause marked tumor regression (Rosenberg &
Vancamp, 1969). The in-vivo tests were performed at the Chester Beatty Institute in
London, United Kingdom. Later, US National Cancer Institute (NCI) conducted clinical
trials on Cisplatin and it was approved by US Food and Drug Administration (FDA) in
1978.
The success of cisplatin led to the synthesis and biological evaluation of many
cisplatin analogues. Much of the effort in the design of new platinum drugs was aimed
mainly at making cisplatin-based therapy safer to patients, especially lessening or
removing unpredictable and severe nephrotoxicity, i.e., damage to kidneys and providing
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oral bioavailability. One other reason is to overcome tumor resistance, either acquired
during cycles of therapy with cisplatin or intrinsic resistance. Synthesis of drugs to
overcome these side effects has proven to be a challenging goal and led to a renewed
optimism in translating the ‘second-generation and third-generation’ platinum drugs into
clinical practice to provide benefit to cancer patients.

1.3 Chemistry of Cisplatin
Cisplatin is generally believed to exert its anticancer activity by interacting with
DNA, inducing programmed cell death. Figure 2 shows the different binding sites for
cisplatin. Guanine-N7 is the preferred site for initial binding of the Pt(II) complex, since
guanine is the most nucleophilic DNA base. Both in-vitro and in-vivo, the majority of
bifunctional DNA adducts formed are intrastrand, i.e., formed between bases on the same
DNA strand, of which approximately 65% is GG adducts, and 25% is AG adducts.

5

Figure 2: Schematic diagram showing various binding sites available for cisplatin
(Lippert, 1999).
Following the success of cisplatin, many studies were performed to determine the
structural features that are required for a platinum compound to exhibit antitumor
activity. Michael and Hoeschele (1973) proposed the structural activity relationship for
platinum compounds. The discoveries of Michael and Hoeschele indicated that the
following structural criteria were necessary for platinum compounds (Michael &
Hoeschele, 1973):
1. The platinum compound should have two amine groups with cis geometry, as
compounds with tsrans geometry are inactive.
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2. The compound should have at least two leaving groups. The two groups should be
in cis geometry with respect to each other. Leaving groups are those groups on the
molecule that are removed most easily.
3. The activity and toxicity of the compound depends upon the ease with which the
leaving groups can be removed.
4. The compound should be neutral.
5. Compounds with less alkyl substituents have greater activity because of greater
availability of protons on the amine group.
Based on these studies, many newer platinum compounds were developed which
are less toxic and less resistant compared to cisplatin. Carboplatin and Oxaliplatin are the
results of two such modifications and are shown in Figure 3.
Carboplatin (Cis-diamine (1,1-cyclobutanedicarboxylato) platinum-II is mainly
used to treat ovarian cancer apart from lung, head and neck cancers. It shows better
antitumor activity, and it is less nephrotoxic than cisplatin, but it is more myelotoxic, i.e.,
depression in bone marrow than cisplatin (Wiltshaw & Kroner, 1976).
Oxaliplatin [Oxalate (2-)-O,O’][1R,2R-cyclohexanediamine-N,N’] platinum-II is
mainly used in the treatment of colorectal cancer. It has some side-effects like
progressive peripheral sensory neuropathy, mild acute neuropathy, diarrhea, vomiting and
hematological suppression (Wiltshaw & Kroner, 1976).
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Figure 3: Structures of Carboplatin & Oxaliplatin
n (Wiltshaw & Kroner, 1976).
1.4 Synthesis of cisplatin
In 1845, Michell Peyrone synthesized cisplatin, but 50 years later its correct
structure, i.e., square planar st
structure with cis and trans configurations was established by
Alfred Werner, for which he was awarded the Nobel prize in 1913 (Alderen, Hall &
Hambley, 2006).
Early methods of cisplatin synthesis produced impur
impuree products and were
unreliable. Many alterations aimed to improve the purity of the product, overall yield, and
reaction time. Dhara (1970) reported a rapid method for the synthesis of cisplatin as
shown in Figure 4, and this method is the basis for the majority of the subsequent
cisplatin
in synthetic methods
methods. In this method, by the addition of saturated solution of KI
(potassium iodide) to the starting material K2(PtCl4), the tetraiodo analogue K2(PtI4) is
formed. Addition of NH3 to K2PtI4 resulted in formation of the yellow product cis-[PtI2
(NH3)2] which is collected, dried and then treated with aqueous AgNO3 (silver
silver nitrate),
nitrate
which causes
auses the precipitation of A
AgI (silver iodide) that is filtered off and discarded.
discard The
filtrate containing [Pt(OH
(OH2)2(NH3)2]2+ was treated with KCl (potassium
ium chloride)
chloride to
precipitate out the final product cisplatin [PtCl2(NH3)2] as yellow powder.
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Figure 4: Synthetic scheme for the Dhara synthesis of cisplatin (Dhara, 1970).
1.5 Mechanism of Action
After the discovery of the biological activity of cisplatin, much research was
conducted for about 35 years in order to elucidate its mechanism of action. Major focus
was on the DNA, i.e., the biological target of the drug, and examining the effects of
cisplatin adducts formation on DNA dependent cellular functions.
Cisplatin is believed to show its anticancer activity by interacting with DNA and
inducing the programmed cell death. Cisplatin is introduced into cancer patients
intravenously along with saline solution. Sixtyfive to ninetyeight percent of the cisplatin
is found to be protein bound after one day of administration (Ivanov et al, 1998). Once
cisplatin is administered, it enters the blood stream and remains intact due to the
relatively high concentration of chloride ions (~100 mM). The un-dissociated compound
then enters into the cell by passive diffusion and very little evidence shows that cisplatin
9

enters into the cell through active transport (Gately & Howell, 1993). Recent studies
showed that cisplatin is transported actively through a copper transporter Ctr1 (Ishida,
Lee, Thiele, & Herskowitz, 2002).
Inside the cell, the un-dissociated cisplatin molecule undergoes hydrolysis,
wherein the chlorine ligand is replaced by a molecule of water. This process generates a
positively charged species which react with the DNA bases, usually guanine, forming a
mono-functional adduct. Hydrolysis occurs inside the cell due to a much lower
concentration of chloride ion (~3-20 mM) and a higher concentration of water inside the
cell. In-vitro studies reveal that mono-aquated forms of the platinum are responsible for
ninetyeight percent of the drug binding to DNA.
Insside the cell:
Pt(II)(NH3)2Cl2 +H2O
[Pt(II)(NH3)2Cl(H2O)]+ + H2O

[Pt(II)(NH3)2Cl(H2O)]+ + Cl[Pt(II)(NH3)2(H2O)2]2+ + Cl-

The N7 position on Guanine (G) is the electron rich site on DNA and 1, 2-GpG, i.e.,
adduct or crosslink formed by binding of cisplatin to two guanines on the same strand of
DNA and 1, 2- ApG, i.e., adduct or crosslink formed by binding of cisplatin to adenine
(A) and a guanine on the same strand of DNA, intra-strand crosslinks are the major
adducts formed in the ratio of 2.5-4:1 respectively. Cisplatin forms bifunctional adducts
with guanine-guanine and adenine-guanine which brings about the distortion of the DNA,
i.e., bent towards the major groove and widening of the minor groove (Takahara,
Rosenzweig, Frederick, & Lippard, 1995). This distortion is recognized by the specific
types of proteins called High Mobility Group (HMG) proteins, which can either initiate
DNA damage repair or signal for apoptosis, which is shown in Figure 5 (Fuertes, Castilla,
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Alosnso, & Perez, 2002).. The binding of HMG proteins to a minor groove results in cell
cycle arrest, replication inhibition
inhibition, transcription inhibition, and cell death (Jamieson &
Lippard, 1999).

Figure 5:: Cytotoxic pathway of cisplatin (Lippert,
Lippert, 1999).
1999)
Once inside the cell, cisplatin can bind to DNA, RNA, cellular proteins, enzymes
or mitochondria. Interaction of cisplatin with mitochondria was unclear. The cytotoxicity
of cisplatin is primarily due to its interaction with nucleophilic N7 sites of purine bases in
DNA to form DNA-DNA
DNA interstrand or intrastrand crosslinks and DNA
DNA-protein
crosslinks as shown in Figure
igure 6. However, evidence strongly favors intrastrand adducts as
lesions largely responsible for the cytotoxic action.
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(A) 1, 2-intrastrand crosslink
link

(B) interstrand crosslink
cross

(C) mono-functional
functional adduct

(D) protein-DNA
protein
crosslink

Figure 6: Adducts formed after binding of cisplatin to DNA (Cepeda et al, 2007).
1.6 Role of Ctr1 in cellular accumulation of Cisplatin
Ctr1 has been recognized as an important copper transporter that is present on the
plasma membrane and distributed on a variety of intracellular membr
membranes.
anes. Ctr1 is one of
the several transporters that mediate the movement of copper ion across the plasma
membrane. Recent studies have suggested a new role for Ctr1 in the cellular
accumulation of the chemotherapeutic drug cisplatin and its analogues. Deletion
Delet
of the
yeast and mouse Ctr1 resulted in an increase in cisplatin resistance and a decrease in
cisplatin accumulation (Sinani, Adle, Kim, & Lee, 2007)
2007). Human ovarian carcinoma
cell lines overexpressing Ctr1 exhibit an increase in cisplatin import into the cell. ATP7A
and ATP7B are the two copper efflux transporters which are also involved in cisplatin
efflux. Although this evidence suggest
suggests that cisplatin uptake and extrusion are mediated
12

by copper transporters, the mechanism by which Ctr1 transports the chemically distinct
copper and cisplatin is poorly understood.
Like copper, in many types of cells, cis-DDP triggers the rapid degradation of
Ctr1 and does that at much lower concentrations and more rapidly than copper. Figure 7
illustrates the concept that, when assembled as a trimer, Ctr1 delivers a series of stacked
rings of methionines, histidines, and cysteines that take part in transchelation reactions to
ensure the regulated movement of copper through Ctr1. The pore formed by the Ctr1
trimer is only 8 Å in diameter. This is large enough to accommodate copper but initially
seems too small to allow passage of the platinum-containing drugs. However,
transmembrane proteins of this type can be quite flexible, and the wall of the pore is
potentially quite expandable. Platinum drugs have square planar configuration and it may
be the ability of each to bind to one or more sulfur atoms of the methionine rings in Ctr1
and to undergo transchelation reactions, which makes them transportable by Ctr1. Loss of
Ctr1 is associated with cisplatin resistance both in-vitro and in-vivo.
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Figure 7: Schematic illustration of the trimeric pore of CTR1 (Howell, Safaei, Larson, &
Sailor, 2010).

1.7 Cisplatin Resistance
Even though cisplatin is very effective in cancer treatment, it faces problems
which most of the drugs face, i.e., drug resistance. Intracellular platinum concentration
plays a key role in the drug resistance. Resistance occurs when cells once destroyed by a
particular drug no longer respond to the same drug. Drug resistance is a major
complication in cancer chemotherapy and accounts for the failure of chemotherapy to
cure cancer in the majority of patients. Cisplatin resistance leads to reduced DNA damage
and this resistance is developed through:
1. Reduced intracellular drug accumulation: The cause of reduced cisplatin
accumulation in cisplatin-resistant cells is due to inhibition of drug uptake or
increase in drug efflux or both. Even though cisplatin is not transported by the
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sodium potassium ATPase pump, its inhibitor Ouabain inhibits drug uptake and
this suggests that cell membrane potential is the cause of the drug accumulation
(Michael & Hoeschele, 1973).
2. Increased inactivation by thiol-containing molecules: Cisplatin is inactivated
by many cytoplasmic constituents including nucleophilic GSH and cysteine-rich
metallothionein (Guo & Sadler, 1999). The concentration of the GSH levels
increases with chronic exposure of cisplatin and induces resistance by decreasing
the level of cisplatin available for interacting with DNA.
3. Increase in DNA damage repair: Another way that cells can become resistant to
cisplatin is to have an enhanced ability to remove cisplatin-DNA adducts and to
repair cisplatin-induced lesions in DNA. Nuclear Excision Repair (NER) pathway
is the major pathway which helps in the removal of the cisplatin DNA adducts.
Cellular defects in this pathway resulted in the hypersensitivity towards cisplatin
(Thor et al., 1998). This ability is shown by certain DNA repair proteins. An
example of such protein is XPE-BF (xeroderma pigmentosum group E binding
factor). When the levels of this protein go up, cisplatin resistance develops.
4. Inhibitors of the apoptosis: Survivin and XIAP are the molecules which are
found to inhibit the apoptosis pathway. These are the direct effectors of the
apoptosis irrespective of the DNA damage pathway (Asselin, Mills, & Tsang,
2001).
5. Dysfunction of the tumor suppressor p53: Stabilization and activation of the
p53 is responsible for apoptosis. Defects in the gene expression result in the
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development of tolerance to the cisplatin because of the failure of the apoptosis
(Kastan, Onyekwere, Sidransky, Vogelstein, & Craig, 1991).

1.8 Binding of Cisplatin to DNA Bases
Many efforts have been made in developing new anticancer drugs which can
overcome the cisplatin resistance or enhance the activity of the drug. Many
computational studies have been put forward in the past and none have been successful in
developing the understanding of the features controlling the interaction of the Pt moiety
with the nucleotide bases (Baik, Friesner, & Lippard, 2003). The models proposed by
computational methods studied the electronic structure changes resulting from Pt−N bond
formation, such as the influence of platination on base pairing and proton affinity.
Cisplatin is mainly found to interact with purine bases, such as adenine and guanine, than
pyrimidines, such as thymine and cytosine. Among purines, it preferentially binds to
guanine than adenine.

1.9 Cisplatin binds more preferably to guanine than adenine. Why?
Many experiments have been performed in order to determine why cisplatin
binds more preferably to guanine than adenine. Theoretical studies of kinetic behavior of
cisplatin binding to guanine and adenine were performed by Baik et al (2003), who
proposed two possible reasons for this behavior, i.e., the hydrogen bonding and the
electronic interactions between the metal center and the lone-pair orbital of N7 of
nucleotide base. Using a series of experimental studies, it was concluded that N7
platination of guanine is both thermodynamically and kinetically more favorable than N7
platination of adenine (Baik, Friesner, & Lippard, 2003).
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The hydrogen bond between an amine ligand of platinum and the oxo group of
guanine plays an important role in stabilizing the Pt-guanine adduct when compared to
Pt-adenine adduct. In the Pt-adenine adduct, Pt-ammine ligand acts as a hydrogen bond
donor, which is not energetically favorable (Baik, Friesner, & Lippard, 2003).
Coordination of Platinum compounds resulted in the formation of GG adducts
(60-65%), and AG adducts (20-25%) (Legendre, Chottard, & Kozelka, 1998); the GA
adducts were not detected for a long time, but the recent findings of Chottard et al
revealed the presence of monoadducts that led to a slow chelation within GA sequences
(Monjardet, Bombard, Chottard, & Kozelka, 2003). Chottard and his research group
performed many computational studies to study the reaction rates of cisplatin with two
oligonucleotides containing GG and AG sequences. They came up with many
conclusions of which they found that the accessibility is the main factor in determining
the sequence dependent binding of Pt compounds to DNA, i.e., the size of the
neighboring bases can influence the reactivity. The flanking bases or adjacent bases can
influence reactivity of guanine via steric clashes (Monjardet, Elizondo, Chottard, &
Kozelka, 2002). If a ligand is bulkier, then we could expect less reaction of A, due to the
steric clashes between the amine at sixth position and the ligand, when compared to G,
which has less bulky O instead.
Another main finding was that the hydrogen bonding plays an important role in Pt
compounds binding to adenine and guanine residues of DNA. Their results suggest that
the ligand cis to the incoming site can influence the reaction through hydrogen bonding
and that G reacts ~6 times faster than A, with the diaqua form of cisplatin which could be
the form that reacts with DNA (Monjardet, Elizondo, Chottard, & Kozelka, 2002).
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The preference for the nucleotide base depends on the size and type of ligand
present on the platinum. The platinum can coordinate at sites other than N7 and N1 of
adenine; the Bierbach experiments on PT-ACRAMTU ([Pt(en)Cl(ACRAMTU-S)](NO3)2
(en = ethane-1,2-diamine, ACRAMTU =1-[2-(acridin-9-ylamino)ethyl]-1,3dimethylthiourea) showed unusual binding to the N3 position (Bierbach & Farrell, 1997).

1.10

Previous Research
A bulky platinum triamine complex, [Pt(Me5dien)(NO3)]NO3 (Me5dien =

N,N,N’,N’,N’’-pentamethyldiethylenetriamine), was reacted with N-acetylmethionine
(N-AcMet) and guanosine 5’ monophosphate (5’-GMP), which led to the formation of
two rotamers of [Pt(Me5dien)(5’-GMP-N7)]+ with 5’-GMP and [Pt(Me5dien)(N-AcMetS)]+ with N-AcMet. The platinum complex was found to react faster with GMP when
compared to N-AcMet (Sandlin, Starling, & Williams, 2010). The slow reactivity of NAcMet was attributed to the steric clashes between the N-AcMet and the methyl group of
the bulky ligand Me5dien.
The opposite trend was observed when a less bulky platinum complex,
[Pt(dien)Cl]Cl was used, i.e., N-AcMet reacts faster than 5’-GMP (Djuran, Lempers, &
Reedijk, 1991). It was anticipated that the bulk of the platinum complex affects the
reactivity. It was believed that the platinum complexes with sufficient bulk are selective
to DNA rather than proteins (Sandlin, Starling, & Williams, 2010).

1.11

Our Approach
Our research focus is to examine how the bulk of the platinum (II) complexes

affects the reaction rate with nucleotide bases. Two platinum (II) triamine complexes,
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[Pt(Me5dien)(NO3)]NO3 which has a bulky ligand Me5dien and [Pt(dien)(NO3)]NO3
which has a less bulky ligand dien, were reacted with 5’-AMP and 5’-GMP
GMP DNA bases,
whose structures are represented in Figures 8 and 9. NMR spectroscopy was used to
study all the reactions. Dynafit software was used to study the rate constants of the
reactions.

Figure 8:: Structures of [Pt(Me5dien)(NO3)]NO3 and [Pt(dien)(NO3)]NO3

Figure 9:: Structures of 5’
5’-Adenosine monophosphate & 5’-Guanosine
Guanosine monophosphate.
monophosphate
s
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2.

EXPERIMENTAL SECTION

2.1 Reagents used
Potassium tetrachloroplatinate(II) (K2PtCl4), N,N,N’,N’,N” pentamethyldiethylene triamine (Me5dien), silver nitrate (AgNO3), sodium
trifluoromethane sulfonate (sodium triflate), deuterium oxide (D2O), and potassium
iodide (KI), were from Aldrich. 5’-Adenosine monophosphate (5’-AMP), 5’-Guanosine
monophosphate (5’-GMP), and diethylenetriamine (dien) were from Acros Organics. All
the reagents were used as such without any further purification.

2.2 Synthesis of platinum diethylenetriamine dinitrate or [Pt(dien)(NO3)]NO3
The synthesis of platinum diethylenetriamine dinitrate involves two steps: the
synthesis of platinum diethylenetriamine dichloride and the reaction of synthesized
platinum diethylenetriamine dichloride with silver nitrate (Guiliano, Matilde, & Bruno,
1995).
(i) Synthesis of chlorodiethylenetriamine platinum (II) chloride:
0.1 g of Potassium tetrachloroplatinate (K2PtCl4) was dissolved in 30 mL of
deionized water. To this solution, 1.0 mL of (98%) diethylenetriamine was added. The
pH of the solution was adjusted to 3 by the addition of 1 M HCI. The solution was
refluxed for about 6 hours. The resulting yellow-colored solution was filtered,
concentrated to 4 mL, and left overnight in a refrigerator. The crystals were removed by
filtration, washed with a small amount of ethanol, and air-dried. The pure complex was
obtained by recrystallization from a small amount of water (Guiliano, Matilde, & Bruno,
1995).
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(ii) Reaction of Platinum diethylenetriamine dichloride with silver nitrate:
100 mg of Platinum diethylenetriamine dichloride was added to an amber vial. 92
mg of silver nitrate and 20 mL deionized water were also added. The sample was then
allowed to stir overnight. The solution was filtered into a 50 mL round bottomed flask
using syringe filtration. The product platinum diethylenetriamine dinitrate was obtained
by evaporating the solution using a rotary evaporator and was then stored and used for
further reactions (Guiliano, Matilde, & Bruno, 1995).

2.3 Synthesis of platinum pentamethyldiethylene triaminedinitrate or
[Pt(Me5dien)(NO3)]NO3
Platinum pentamethyldiethylenetriamine dinitrate was synthesized by using a
method described by Cini et al. (1998), except for the use of silver nitrate instead of silver
triflate. The synthesis involves two steps: The synthesis of [Pt(Me5dien)I]2(Pt2I6)
followed by the reaction of synthesized [Pt(Me5dien)I]2(Pt2I6) with silver nitrate.
(i) Synthesis of [Pt(Me5dien)I]2(Pt2I6):
0.5 g of potassium tetrachloroplatinate (K2PtCl4) was dissolved in 5 mL of
deionized water. 0.82g of potassium iodide (KI) was added at 50ºC. To this solution, 250
µL of pentamethyl diethylenetriamine was added. The solution was allowed to stir for
one hour at 50ºC on a magnetic stirrer. Yellow-green precipitate was filtered off using
gravitational filtration. The separated precipitate was washed with water and air dried for
2 days (Cini, Intini, Maresca, Pacifico, & Natlie, 1998).
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(ii) Reaction of [Pt(Me5dien)I]2(Pt2I6) with silver nitrate:
300 mg of [Pt(Me5dien)I]2(Pt2I6) was added to a 20 mL of deionized water in an
amber vial. 98.5 g of silver nitrate was also added. The resultant mixture was allowed to
stir overnight on a magnetic stirrer. The solution was filtered using syringe filtration and
the filtrate was evaporated to dryness using a rotary evaporator. The obtained product
was stored and used as and when needed.

2.4 Preparation of Stock Solutions
•

Stock solution of Pt(Me5dien): 4.92 mg of Platinum pentamethyldiethylene
triamine dinitrate-Pt(Me5dien)(NO3)2 [Mol Wt – 492.45 g] was dissolved in 1 mL
of D2O to obtain a 10 mM solution.

•

Stock solution of Pt(dien): 4.22 mg Platinum diethylenetriamine dinitratePt(dien)(NO3)2 [Mol Wt – 422.5 g] was dissolved in 1 mL of D2O to obtain a 10
mM solution.

•

Stock solution of 5’-AMP: 3.47 mg of 5’-Adenosine monophosphate (5’-AMP)
[Mol Wt – 347.2 g] was dissolved in 1 mL of D2O to obtain a 10 mM
concentrated solution.

•

Stock solution of 5’-GMP: 4.07 mg of 5’-Guanosine monophosphate (5’-GMP)
[Mol Wt – 407.19 g] was dissolved in 1 mL of D2O to obtain a 10 mM
concentrated solution.

•

Stock solution of sodium triflate: Molecular weight of Sodium triflate is 172.2 g.
1.72 mg sodium triflate was dissolved in 1 mL of D2O to obtain a 10 mM
concentrated solution.
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Solutions of required concentrations were prepared and used when needed.

2.5 Methods
A JEOL Eclipse 500 MHz Nuclear Magnetic Resonance was used to characterize
the products. Deuterium oxide (D2O) was used as solvent for characterization. 1H-NMR
spectroscopy was used to study all the reactions. Heteronuclear Multiple Quantum
Coherence (HMQC) Spectroscopy was used to study the products formed by the reaction
of Pt(Me5dien) and AMP.
Solutions used for pH adjustment:
1% deuterated nitric acid and 1% sodium deuteroxide were used to adjust the pH
of all the solutions used.
Reaction of [Pt(Me5dien)(NO3)]NO3 and 5’-Adenosine monophosphate:
A 300 µL aliquot of a 5 mM stock solution of Pt(Me5dien) was mixed with a 300
µL aliquot of a 10 mM stock solution of 5’-AMP. The NMR tube was kept in a water
bath for about half an hour, maintained at 25ºC. The pH of the solution was adjusted to 4
before taking spectra.
Reaction of [Pt(Me5dien)(NO3)]NO3 and 5’-Guanosine monophosphate:
A 300 µL aliquot was taken from a mixture of 10 mM 5’-GMP and 100 mM
sodium triflate and added to a 300 µL aliquot of a 20 mM Pt(Me5dien). The pH of both
solutions was adjusted to 4 prior to mixing. 1H-NMR kinetics scan was used study the
reaction. This kinetics method was made to scan every 10 min for 2 hours.
Reaction of [Pt(dien)(NO3)]NO3 and 5’-Adenosine monophosphate:
A 400 µL aliquot of 10mM [Pt(dien)(NO3)]NO3 was added to the mixture of 100
µL aliquot of 10 mM 5’-AMP and 500 µL of D2O . The pH of both solutions was
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adjusted to 4 prior to mixing. 1H-NMR kinetics scan was used study the reaction. This
kinetics method was made to scan every 5 min for 1.5 hours.
Reaction of [Pt(dien)(NO3)]NO3 and 5’-Guanosine monophosphate:
A 30 µL aliquot of 10mM [Pt(dien)(NO3)]NO3 was added to the mixture of 15 µL
aliquot of 10 mM 5’-GMP and 955 µL of D2O. The pH of both solutions was adjusted to
4 prior to mixing. 1H-NMR kinetics scan was used study the reaction. This kinetics
method was made to scan every 5 min for 1 hour.
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3.

RESULTS

3.1 Reaction of [Pt(Me5dien)(NO3)]NO3 and 5’-AMP
The 1H-NMR
NMR spectrum was obtained immediately after mixing solutions of 2.5
mM of [Pt(Me5dien)(NO3)]NO3 and 5 mM of 5’-AMP.
AMP. The pH of both solutions was
adjusted to 4 prior to mixing.

Figure 10: (C) is the product for
formed by the coordination of [Pt(Me5dien)(NO3)]NO3
complex (A) at N7 position of (B).
There are two possibilities of Pt(Me5dien) complex to react with AMP. It can get
coordinated to N7 position or at the N1 position of Adenine as shown in Figures 10 & 11.
11
Four sets of new resonances were observed: two with downfield shifted H8 signals and
two with downfield shifted H2 signals according to the HMQC spectrum. The downfield
chemical shifts of H8 and H2 protons were observed due to N7 and N1 coordination
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respectively.
ectively. New product signals appear in the NMR spectrum corresponding to two
different coordinations.

Figure 11: (C) is the product formed by the coordination of [Pt(Me5dien)(NO3)]NO3
complex (A) at N1 position of (B).
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Figure 12:: Partial NMR spectra of the reaction of Pt(Me5dien) and 5’-AMP
AMP on day 1 &
12.
The NMR spectrum did not show any signal for the product on the first day,
which indicates that there was no reaction between AMP and [Pt(Me5dien)(NO
en)(NO3)]NO3.
As in Figure 12, the
he spectrum showed three prominent peaks aatt the following chemical
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shifts: H1’ at 6.06 ppm, H2 signal at 8.23 ppm, H8 signal at 8.45 ppm. These peaks were
corresponding to unreacted AMP.
After 12 days, many new peaks appeared in the NMR spectrum. HMQC
spectroscopy was used to study the reaction of [Pt(Me5dien)(NO3)]NO3 and AMP. This is
a Two-Dimensional NMR spectroscopy technique, a correlation technique that allows the
determination of carbon and hydrogen connectivity.
In the spectrum obtained after 12 days, the four new peaks found downfield to the
H8 peak of the unreacted AMP, were assigned as H8 and H2 product peaks and this
assignment was confirmed based on the results obtained by HMQC experiment. The two
H8 peaks were found at chemical shifts of 9.29 and 9.21 ppm and two H2 peaks at 8.41
and 8.60 ppm. H8 peaks were found to be more downfield than H2 peaks. This downfield
shift of the H8 and H2 product peaks from H8 of unreacted AMP indicates the N7 and N1
coordination, respectively. Two sets of resonances are observed for each H8 and H2
signal, due to slow rotation around the Pt-N7 or Pt-N1bond.
The chemical shifts of two other peaks found in between H8 and H2 of the
unreacted AMP are at 8.26 and 8.29 ppm. These new peaks are assigned as the H2s of N7
coordination. The H8 peaks corresponding to the N1 coordination were partially obscured
by unreacted AMP. The product peak of H1’ was observed at 6.14 ppm, which is
downfield to H1’ of unreacted AMP. The spectrum suggests that the reaction of
Pt(Me5dien) with AMP resulted in approximately equal reaction at both N7 and N1
positions. The reaction of Pt(Me5dien) with AMP was very slow in that it took 12 days to
observe the product signals in the NMR spectrum.
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The rate of reaction was estimated to be 0.00003 M-1s-1. The result described by
R.D Sandlin et al (2010), showed the rate constant of 0.02 M-1s-1 for the reaction of
[Pt(Me5dien)(NO3)]NO3 and 5’-GMP at concentrations of 3.33mM each, which suggests
that the cisplatin analog [Pt(Me5dien)(NO3)]NO3 reacts at a very slow rate with AMP
when compared to GMP (Sandlin, Starling, & Williams, 2010).

3.2 Reaction of [Pt(Me5dien)(NO3)]NO3 and 5’-AMP at different temperatures
A 500 µL aliquot of [Pt(Me5dien)(NO3)]NO3 (40 mM) solution was mixed with
250 µL of 5’-AMP (40 mM) and 250 µL of sodium triflate 400 mM. The pH of the
solution was adjusted to 4 and the NMR tube was stored in a water bath maintained at
25ºC. After 30 days, the pH was adjusted to 4 and 1H-NMR scan was used to study the
reaction at different temperatures of 25, 40, 60, and 80 ºC and the spectra are shown in
Figure 13.
The NMR spectra were analyzed for peak broadening of H8s and H2s of the
products formed in the reaction. There was no significant peak broadening or coalescence
when the temperature was increased from 25ºC to 40, 60, 80 ºC, indicating that the
exchange between the rotamers is very slow. [Pt(2,2’-bipiperidine)(5’-GMP)2] also
showed similar results due to slow rotation (Susan, Intini, Natlie, & Marzilli, 1998). From
the experiments by Reily and Marzilli (1986), peak broadening of the H8 peaks of the
Pt(en)(5’-dAMP-N7) complex was observed when the temperature was increased, which
is in contrast with the Pt(Me5dien) and AMP reaction (Reily & Marzilli, 1986).
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Figure 13:: Partial NMR spectra showing the reaction of Pt(Me5dien) and AMP at
temperatures of 25, 40, 60, and 80 ºC.

3.3 Reaction of [Pt(Me5dien)(NO3)]NO3 and 5’-GMP
The [Pt(Me5dien)(NO3)]NO3 complex
plex was allowed to react with 5’-GMP
5’
at 3.33
mM and 3.33 mM concentrations respectively. The pH of the solutions was adjusted to 4
using a suitable buffer solution before mixing. The 1H-NMR
NMR Kinetics scan was used to
run the reaction which scans the reaction every 10 min for 2 hours.

30

As shown in Figure 14, tthe downfield shift of product H8 peak indicates the N7
coordination of [Pt(Me5dien)(NO3)]NO3 complex to guanine.

Figure 14: (C) is the product formed by the coordination of [Pt(Me5dien)(NO3)]NO3
complex (A) at N7 position of 5’-GMP (B).
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Figure 15:: Partial NMR spectrum of reaction of [Pt(Me5dien)(NO3)]NO3 and GMP at 10,
70 & 120 min interval.
In the above spectrum
spectrum, Figure 15, the reaction within 10 min interval shows
signals at chemical shifts of 5.85 and 8.05 ppm, which correspond to H1’,
’ i.e., the
hydrogen from the deoxyribose ring of GMP and H8 of guanine respectively. Unlike the
reaction of Pt(Me5dien) and AMP, wherein the product peak did not appear until after 12
days, in this reaction the product peak started showing up within 10 min. The initial
product signal was observed at 8.85 ppm.
The reaction within 70 min interval shows prominent signals for H8 of the
product. The H8 signals ap
appear
pear at 8.75 and 8.85 ppm. Previous studies revealed that the
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Me5dien ligand does not have a C2 symmetry (Cini, Intini, Maresca, Pacifico, & Natlie,
1998), thus these peaks were assigned as rotamers of the complex [Pt(Me5dien) (5’GMP- N7)]+ (Sandlin, Starling, & Williams, 2010). Two sets of resonances are observed
for H8 signal due to slow rotation around the Pt-N7 bond. The reaction proceeds in the
forward direction leading to the formation of the product. The product peak intensity
increases with time. It is clearly shown within 120 min interval that the H8 peak height of
unreacted 5’-GMP decreased and the H8 and H1’ product peak heights of product 5’-GMP
increased with time.
The [Pt(Me5dien)(NO3)]NO3 complex was found to coordinate at N7 position of
guanine and the rate of reaction was previously estimated to be 0.02 M-1s-1 (Sandlin,
Starling, & Williams, 2010).

3.4 Reaction of [Pt(dien)(NO)3]NO3 and 5’-AMP
The [Pt(dien)(NO3)]NO3 complex was allowed to react with 5’-AMP at a
concentration of 1 mM and 4 mM respectively. The pH of the solutions was adjusted to 4
using a suitable buffer solution before mixing. The 1H-NMR kinetics scan was used to
run the reaction which scans for every 5 min for 1.5 hours.
As shown in Figure 16, the downfield shift of product H8 peak indicates the N7
coordination of [Pt(dien)(NO3)]NO3 to AMP.
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Figure 16: (C) is the product formed by the coordination of [Pt(dien)(NO3)]NO3 (A) at N7
position of AMP (B).
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Figure 17:: Partial NMR spectrum of reaction of [Pt(dien)(NO3)]NO3 and AMP at 10, 20
& 80 min interval.
In the above stacked NMR spectra, Figure 17, the spectrum at 10 min shows two
peaks at chemical shifts of 8.20 and 8.42 ppm, whic
which corresponds to the unreacted 5’5’
AMP. The peak corresponding to H8 of product 5’-AMP
AMP was found downfield in the
spectrum within 20 min of time. The initial product peak of H8 was found at 8.87 ppm
and H2 was found at 8.21 ppm. The H8 product peak was broader.
er. The product H8 peak of
Pt(en)(5’-dAMP-N7) also showed a similar broader peak in the experiment conducted
c
by
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Reily and Marzilli (1986) due to restricted rotation around Pt-N7 bond (Michael & Luigi,
1986).
The peak height of product H8 and H2 increased with time and the intensity of H8s
& H2s of the unreacted AMP decreased significantly with time. The rate of reaction was
estimated to be 0.188M-1s-1.

3.5 Reaction of [Pt(dien)(NO3)]NO3 and 5’-GMP
The [Pt(dien)(NO3)]NO3 complex was allowed to react with 5’-GMP at 0.3 mM
and 0.15 mM concentrations respectively. The pH of the solutions was adjusted to 4
using a suitable buffer solution before mixing. The 1H-NMR kinetics scan was used to
run the reaction which scans the reaction every 5 min for 1 hour. The downfield shift of
product H8 indicates the N7 coordination of Pt(dien) to GMP which is shown in Figure
18.
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Figure 18: (C) is the product formed by the coordination of [Pt(dien)(NO3)]NO3 (A) at N7
position of GMP (B).
In the stacked partial NMR spectra, Figure 19, the spectrum
um within a 10 min
interval showed peaks at chemical shifts of 5.95 and 8.73 ppm. The H1’ of deoxyribose
sugar of GMP was at 5.9 ppm and the H8 of guanine was at 8.73 ppm. The distinct H8s
and H1’ signals of unreac
unreacted GMP are not seen in the spectra because of the low
concentration; they are indistinguishable from the noise. The intensity of product signal
tends to increase prominently with time in the spectra within 35 and 60 min.
The rate of reaction was estimated to be 7.32 M-1s-1. When higher concentrations
of Pt(dien) and GMP were used, the reaction almost reached completion within a 10 min
interval. So, as to observe the reaction rate, the reaction was started with very low
concentrations of 0.3 mM of Pt(dien
Pt(dien)) and 0.15 mM of GMP. Even at this low
concentration, the H8s and H1’ of the unreacted GMP could not be seen.
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Figure 19: Partial NMR spectrum of reaction of [Pt(dien)(NO3)]NO3 and 5’-GMP at 10,
35 & 60 min interval.
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Table 1: Rate constants of cisplatin analogs with nucleotide bases.
Cisplatin analog

Nucleotide

Rate Constant (M-1s-1)

[Pt(dien)(NO3)]NO3

5’-GMP

7.32

[Pt(dien)(NO3)]NO3

5’-AMP

0.188

[Pt(Me5dien)(NO3)]NO3

5’-GMP

0.02

[Pt(Me5dien)(NO3)]NO3

5’-AMP

0.00003
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4.

DISCUSSION

In our research, we reacted the cisplatin analogs, Pt(Me5dien) and Pt(dien) with
the 5’-AMP and 5’-GMP nucleotides. We used NMR spectroscopy to study the reaction
patterns. Dynafit software was used to find the rate constants of reactions. Our main
focus was to study how the bulk significantly affects the reaction rate of cisplatin analogs
when reacted with nucleotides.
Previous research was based on the reaction of a bulky triamine complex
[Pt(Me5dien)NO3]NO3 with 5’-GMP and N-acetylmethionine separately. The separate
reactions resulted in a slower reaction with N-AcMet than with 5’-GMP. The competition
reactions showed a significant decrease in the formation of [Pt(Me5dien)(N-AcMet-S]+
complex when compared to [Pt(Me5dien)(5’-GMP)]+ complex (Sandlin, Starling, &
Williams, 2010).
Previously, [Pt(dien)Cl]Cl was reacted with 5’-GMP and N-acetylmethionine and
produced an exact opposite result, i.e., it reacts faster with N-AcMet when compared to
GMP (Djuran, Lempers, & Reedijk, 1991), because the size of the Me5dien ligand
impacted these targets differently. We hypothesized that the AMP ligand would be
affected more than the GMP ligand by the increased size of the Me5dien, as the former
has the larger amino group at the sixth position.
In our research, [Pt(Me5dien)NO3]NO3 was reacted with both 5’-AMP and 5’GMP in separate reactions at pH 4. When the [Pt(Me5dien)NO3]NO3 complex was
reacted with 5’-GMP, two new sets of resonances were observed. The resonances were
assigned to two rotamers of [Pt(Me5dien)(5’-GMP-N7)]+ and the rate constant was
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previously estimated to be 0.02 M-1s-1 (Sandlin, Starling, & Williams, 2010). The
downfield shift of H8 of product indicates the N7 coordination.
When the [Pt(Me5dien)NO3]NO3 complex was reacted with 5’-AMP four new
sets of resonances appeared, each with one signal downfield from the H8 and H2 of the
unreacted AMP. These peaks were assigned as two H8s and two H2s by performing a 2-D
Heteronuclear Multiple Quantum Coherence Spectroscopy. The downfield shifted H8 and
H2 resonances are the results of N7 and N1 coordination respectively. The rate constant
was estimated to be 0.00003 M-1s-1.
When compared to the reaction of Pt(Me5dien) and AMP, the reaction of
Pt(Me5dien) and GMP proceeds much faster, i.e., the ratio of their rate constants is 1:
~650. The bulk of Me5dien ligand significantly slowed the reaction with AMP more than
with the GMP such that it took almost 12 days for the product signals to appear whereas
for Me5dien and GMP, it just took 10 min for the product peak to show up in the NMR
spectrum.
The [Pt(dien)NO3]NO3 complex was reacted with both 5’-AMP and 5’-GMP in
separate reactions at pH 4. When the [Pt(dien)NO3]NO3 complex was reacted with 5’GMP, a peak corresponding to H8 of product appeared and the intensity was found to
increase with time. The reaction was so fast that the unreacted GMP got mixed with noise
of the NMR spectrum. The rate constant of the reaction was estimated to be 7.32 M-1s-1.
When the [Pt(dien)NO3]NO3 complex was reacted with 5’-AMP, the H8 product
peak appeared downfield from the H8 peak of unreacted AMP, indicating the N7
coordination. The rate constant of the reaction was estimated to be 0.188 M-1s-1.
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Several previous studies from the Marzilli lab with 5’-AMP and 5’-GMP
concluded that restricted rotation around the Pt-N7 bond was observed for 5’-GMP when
the ligand is bulky. Later, they found that the products from reaction with the AMP,
showed restricted rotation around the Pt-N7 bond even when the ligand is not bulky,
whereas the product from reaction with GMP showed restricted rotation when the ligand
is bulky (Reily &Marzilli, 1986). The experiments by Cramer and Dahlstrom revealed
that the complexes with a bulky ligand group shows restricted rotation, which is
evidenced by the appearance of two H8 signals. When 195Pt-NMR spectroscopy was used,
the Pt compounds were found to preferably bind N7 when compared to N1 of 5’-AMP by
a ratio of ~10:1 and these observations suggest appreciable steric effects of the 6-NH2
group of 5’-AMP and the high selectivity of Pt compounds for guanine residues may be
because of the steric effects (Reily &Marzilli, 1986).
Our results are in agreement with the findings of Reily and Marzilli, that the
product peak of Pt(dien) and AMP is broader due to the restricted rotation around the PtN7 bond. The reaction with Me5dien and GMP showed two product peaks, which is
supported by the findings of Reedjik and group (Reedjik, 1999). According to a study
conducted by Bierbach, monofunctional PT-ACRAMTU uniquely targets the N3 position
of adenine present in the minor groove of DNA, which is in contrast to traditional
cisplatin analogs that bind to N7 or N1 position of adenine.
The reaction of Pt(dien) and GMP was faster in comparison to reaction of Pt(dien)
and AMP, which indicates that the Guanine is the primary target and Adenine is the
secondary target of Pt(dien) ligand. Adenosine is considered less reactive when compared
to guanosine most probably because of the presence of the bulkier NH2 (amine) group of
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the adenine than the O (oxo) group of guanine at the sixth position (Green, Garner, &
Orton, 1992). Me5dien, which is bulky, does not have the ability to form a hydrogen bond
to the purine bases whereas dien, which is non-bulky, does. However, if hydrogen
bonding is a key factor in the reactivity, then we would expect the Me5dien ligand to
disfavor GMP more than AMP since the former is thought to participate in hydrogen
bonding with ligands cis to the available coordination site (Legendre, Bas, Kozelka, &
Chottard, 2000). The decrease in the reactivity of Me5dien with adenine more than with
guanine is accounted towards steric effects rather than hydrogen bonding; steric effects
have previously been found to influence reactivity of cisplatin metabolites with DNA
sequences (Monjardet, Elizondo, Chottard, & Kozelka, 2002).
In conclusion, the reaction rates of cisplatin analogs, Pt(Me5dien) and Pt(dien)
with 5’-GMP and 5’-AMP were studied using NMR spectroscopy. 5’-GMP reacts faster
than 5’-AMP with both platinum complexes. The bulk of the Me5dien ligand significantly
slows reaction with both GMP and AMP when compared to the dien ligand. Pt-Me5dien
leads to reaction at both N7 and N1 positions of AMP. The reaction was approximately
equal at both N7 and N1 positions, which was confirmed by the data obtained by using
HMQC. Bulk would slow down the reaction with AMP more than GMP. GMP is ~40
times faster than AMP when reacted with Pt(dien) but ~700 times faster than AMP with
Pt(Me5dien).
It is our understanding that platinum compounds with bulky amine ligands may
slow down the reaction of AMP when compared to GMP. Platinum was found to
coordinate both at sites other than N7, i.e., at N1 or N3. Since GG adducts are favored
~3:1 over AG adducts by cisplatin metabolites, we would expect that cisplatin analogs
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with larger amine ligands would show a substantial favoring of GG adductss over other
types of intrastrand crosslinks.
The order of reactivity of Cisplatin analogs with nucleotides was found to be
Pt(dien)(GMP) > Pt(dien)(AMP) > Pt(Me5dien)(GMP) > Pt(Me5dien)(AMP).
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